GlassScriptPhysician profile
Meizhu Chen
NPI 1770152969
$4,966.59
in general payments reported to CMS, 2019-2025
33 companies · $2,356 in 2025
The $2,356 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $284 · 2024: $2,327 · 2025: $2,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,134 · Education: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,133.97 |
| Education | $548.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $509.51 | 2024-2025 | Enhertu, Tagrisso, Imfinzi |
| Janssen Biotech, INC. | $497.64 | 2024-2025 | Erleada, Talvey, Darzalex |
| Daiichi Sankyo INC. | $476.38 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Merck Sharp & Dohme LLC | $416.54 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Exelixis INC. | $385.00 | 2024-2025 | Cabometyx |
| Incyte Corporation | $292.67 | 2024-2025 | Monjuvi, Pemazyre, Jakafi |
| Esperion Therapeutics, INC. | $283.70 | 2022 | |
| Eisai INC. | $241.01 | 2024-2025 | |
| Stemline Therapeutics INC. | $219.70 | 2024-2025 | Orserdu, Elzonris |
| Astellas Pharma US INC | $189.33 | 2024-2025 | Vyloy, Xtandi, Padcev |
| Taiho Oncology, INC. | $163.19 | 2024-2025 | |
| Gilead Sciences, INC. | $151.88 | 2024-2025 | Trodelvy |
| Coherus Oncology, INC. | $148.12 | 2024 | |
| Lilly USA, LLC | $115.71 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $99.95 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $84.67 | 2025 | |
| Puma Biotechnology, INC. | $78.48 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.64 | 2024 | Ninlaro, Vpriv |
| Pfizer INC. | $66.84 | 2024-2025 | |
| Blueprint Medicines Corporation | $64.78 | 2024 | Ayvakit |
| Karyopharm Therapeutics INC. | $60.34 | 2024 | Xpovio |
| Mirati Therapeutics, INC. | $56.78 | 2024 | Krazati |
| Celgene Corporation | $51.48 | 2025 | Reblozyl |
| Genmab U.S., INC. | $45.83 | 2025 | Tivdak, Epkinly |
| Tactile Systems Technology INC | $28.32 | 2025 | Nimbl, Flexitouch Plus |
| Bayer Healthcare Pharmaceuticals INC. | $27.67 | 2024 | |
| Azurity Pharmaceuticals, INC. | $22.68 | 2025 | Danziten |
| Kyowa Kirin, INC. | $21.99 | 2024 | Poteligeo |
| Exact Sciences Corporation | $19.37 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.44 | 2025 | |
| Syndax Pharmaceuticals, INC. | $18.21 | 2025 | Revuforj |
| Tersera Therapeutics LLC | $16.52 | 2025 | Zoladex |
| Amgen INC. | $16.22 | 2025 | Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meizhu Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.